DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Artificial Intelligence in Tumor Evolution: Understanding Cancer Complexity Through Multi-Modal Data Integration in Precision Oncology
This article belongs to the Special Issue The Artificial Intelligence to the Rescue of Cancer Research, Cancer research has undergone a fundamental transformation in recent decades due to the integration of artificial intelligence (AI) models into the study of tumor biology. However, tumor evolution, driven by genetic and phenotypic alterations leading to heterogeneity, resistance and metastasis, remains a major challenge in oncology. To understand these processes is crucial for developing effective therapeutic strategies and improving patient outcomes. Conventional methods often fail to capture the complexity and dynamics of these processes. In contrast, AI tools have the ability to integrate and analyze large-scale multi-omics, imaging and clinical data, offering the capability to decode tumor complexity. AI-driven methods facilitate multi-modal data integration, enabling the recognition of patterns that connect molecular alterations with phenotypic outcomes. In functional genomics, AI tools predict the effects of genetic variants, identify regulatory elements and map dysregulated pathways, thus clarifying mechanisms underlying tumor development and resistance. In the imaging field, deep learning techniques improve tumor segmentation, characterization and longitudinal monitoring, providing more accurate insights into tumor progression and treatment response. Predictive modeling could allow the anticipation of tumor evolution and drug response, supporting adaptive therapeutic plans and real-time treatment adjustments. Moreover, AI supports biomarker discovery, patient stratification and decision support systems that can improve clinical trial design and accelerate the development of personalized therapies. However, these advances raise important ethical challenges, including data privacy, algorithmic bias and the preservation of patient autonomy. Addressing these concerns is essential to ensure the responsible deployment of AI in oncology., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. This research work was funded by the European Commission—NextGenerationEU, through the Momentum CSIC Program: Develop Your Digital Talent. AES, staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 PID2024-155394OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 RED2024-153635-T
DOI: http://hdl.handle.net/10261/440012, https://api.elsevier.com/content/abstract/scopus_id/105041328629
HANDLE: http://hdl.handle.net/10261/440012, https://api.elsevier.com/content/abstract/scopus_id/105041328629